ArticleCancer2019
Treatment capacity required for full-scale implementation of lung cancer screening in the United States.
Article in Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Strategies for sustainable lung cancer screening: a multi-faceted perspective to long-term surveillance in SOLACE.Insights into imaging · 2026Article
- The accuracy of administrative data in identifying pulmonary metastases: a population-based study in Northern Italy.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026Article
- Article
- Natural history models for lung Cancer: A scoping review.Lung cancer (Amsterdam, Netherlands) · 2025Article
- Current Evidence for a Lung Cancer Screening Program.Portuguese journal of public health · 2024Review
- The Impact of Model Assumptions on Personalized Lung Cancer Screening Recommendations.Medical decision making : an international journal of the Society for Medical Decision Making · 2024Article
- Video-Assisted vs Robotic-Assisted Lung Lobectomies for Operating Room Resource Utilization and Patient Outcomes.JAMA network open · 2024Article
- How will lung cancer screening and lung nodule management change the diagnostic and surgical lung cancer landscape?European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Surgical markup in lung cancer resection, 2015-2020.JTCVS open · 2023Article
- Risk Model-Based Lung Cancer Screening : A Cost-Effectiveness Analysis.Annals of internal medicine · 2023Article
- Role of exosomes in non-small cell lung cancer and EGFR-mutated lung cancer.Frontiers in immunology · 2023Review
- Identification of patient characteristics associated with survival benefit from metformin treatment in patients with stage I non-small cell lung cancer.The Journal of thoracic and cardiovascular surgery · 2022Article
- Lung Cancer Diagnosed Through Screening, Lung Nodule, and Neither Program: A Prospective Observational Study of the Detecting Early Lung Cancer (DELUGE) in the Mississippi Delta Cohort.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Observational
- The Future of Lung Cancer Screening: Current Challenges and Research Priorities.Cancer management and research · 2022Review
- Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening.JAMA oncology · 2021Article
- Evaluation of Population-Level Changes Associated With the 2021 US Preventive Services Task Force Lung Cancer Screening Recommendations in Community-Based Health Care Systems.JAMA network open · 2021Article
- Lung cancer screening in Europe: where are we in 2021?Translational lung cancer research · 2021Review
- Implementation of lung cancer screening: what are the main issues?Translational lung cancer research · 2021Review
- Uptake of minimally invasive surgery and stereotactic body radiation therapy for early stage non-small cell lung cancer in the USA: an ecological study of secular trends using the National Cancer Database.BMJ open respiratory research · 2020Article
- Update on screening for lung cancer.Translational lung cancer research · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundFull-scale implementation of lung cancer screening in the United States will increase detection of early stages. This study was aimed at assessing the capacity required for treating those cancers.
methodsA well-established microsimulation model was extended with treatment data from the National Cancer Database. We assessed how treatment demand would change when implementing lung cancer screening in 2018. Three policies were assessed: 1) annual screening of current smokers and former smokers who quit fewer than 15 years ago, aged 55 to 80 years, with a smoking history of at least 30 pack-years (US Preventive Services Task Force [USPSTF] recommendations); 2) annual screening of current smokers and former smokers who quit fewer than 15 years ago, aged 55 to 77 years, with a smoking history of at least 30 pack-years (Centers for Medicare and Medicaid Services [CMS] recommendations); and 3) annual screening of current smokers and former smokers who quit fewer than 10 years ago, aged 55 to 75 years, with a smoking history of at least 40 pack-years (the most cost-effective policy in Ontario [Ontario]). The base-case screening adherence was a constant 50%. Sensitivity analyses assessed other adherence levels, including a linear buildup to 50% between 2018 and 2027.
resultsThe USPSTF policy would require 37.0% more lung cancer surgeries in 2015-2040 than no screening, 2.2% less radiotherapy, and 5.4% less chemotherapy; 5.7% more patients would require any therapy. The increase in surgical demand would be 96.1% in 2018, 46.0% in 2023, 38.3% in 2028, and 24.9% in 2040. Adherence strongly influenced results. By 2018, surgical demand would range from 52,619 (20% adherence) to 96,121 (80%). With a gradual buildup of adherence, the increase in surgical demand would be 9.6% in 2018, 38.3% in 2023, 42.0% in 2028, and 24.4% in 2040. Results for the CMS and Ontario policies were similar, although the changes in comparison with no screening were smaller.
conclusionsFull-scale implementation of lung cancer screening causes a major increase in surgical demand, with a peak within the first 5 years. A gradual buildup of adherence can spread this peak over time. Careful surgical capacity planning is essential for successfully implementing screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.